Allotment Status of Modern Diagnostic & Research Centre IPO

As investors await the Modern Diagnostic IPO allotment status, the next step is to know where and how to check the allocation once the allotment is finalised.

The allotment status can be checked online using PAN, application number, or demat details on the official platforms.

Investors can:

• Check on the registrar website (MUFG Intime India) by selecting the IPO name and entering PAN or application details
• Check on the BSE website using PAN or application number under the equity issue section

With allotment expected shortly, investors are advised to keep their application details ready and rely only on official registrar and exchange portals for accurate allotment information.

As investors await the Modern Diagnostic IPO allotment status, many are assessing their chances of receiving allotment, especially after the issue closed with an exceptionally high subscription.

The IPO was subscribed 350.49 times overall, with the retail category subscribed 342.46 times, the NII segment at 519.38 times, and the HNI portion alone at 856.35 times. At these levels, the number of applications far exceeds the shares available in each category.

For retail investors, allotment is done through a lottery-based system, where each valid application has an equal chance of receiving one lot, regardless of the number of lots applied for. This means applying for more lots does not improve the probability of allotment.

In the NII and HNI categories, allotment is proportional, but heavy oversubscription significantly reduces the likelihood of receiving a meaningful allocation, and many applicants may receive no shares.

With demand far outstripping supply, the IPO allotment status outcome will depend largely on the draw of lots for retail investors and proportional allocation for non-institutional bidders, making patience key as the final results are awaited.

After a blockbuster response that pushed subscription to 350 times, the Modern Diagnostic IPO has moved decisively into the allotment phase. With bidding now closed, investor focus has narrowed to a single question — the IPO allotment status.

Given the scale of oversubscription across retail, HNI, and institutional categories, the allotment outcome will be highly competitive, particularly for retail applicants where allocation follows a lottery-based process.

As the post-issue formalities progress, the allotment status update is expected shortly, setting the stage for refunds, share credit, and the stock’s listing on the BSE SME platform. Investors are advised to monitor official channels closely for the final allocation outcome.

As investors track the Modern Diagnostic IPO allotment status, the exceptionally high subscription levels provide a clear picture of how competitive allotment is likely to be across categories.

Retail Individual Investors (RII)
The retail portion was subscribed 342.46 times. In this category, allotment is done through a lottery system, where each valid application has an equal chance of receiving one lot. Applying for multiple lots does not improve the probability. With subscription running into the hundreds, the chance of allotment is low and purely luck-based.

Non-Institutional Investors (NII)
The NII category was subscribed 519.38 times overall.

• The HNI portion alone saw subscription of 856.35 times, making allotment extremely competitive.
• In this category, allotment is proportional rather than lottery-based, but given the scale of oversubscription, the effective allocation per application is expected to be very small, and many applicants may receive no shares.

Qualified Institutional Buyers (QIBs)
The QIB segment was subscribed 193.51 times. While this category does not involve retail-style lottery, allocation is based on institutional bidding and discretion. High subscription indicates strong institutional interest, but it does not directly affect retail allotment chances.

In summary, with overall subscription at 350.49 times, allotment across categories is highly competitive. For retail investors, the IPO allotment status outcome will depend entirely on the draw of lots, while for NII applicants, proportional allocation amid heavy demand significantly reduces the likelihood of meaningful allotment.

For retail applicants tracking the Modern Diagnostic IPO allotment status, competition remains extremely high. The retail portion of the issue was subscribed 342.46 times, indicating demand far exceeded the shares available.

Allotment in the retail category follows a lottery-based mechanism, where each valid application has an equal chance of receiving one lot, irrespective of the number of lots applied for. At these subscription levels, the probability of allotment is low and purely luck-driven.

The Modern Diagnostic IPO allotment status is most competitive in the non-institutional investor category. The NII segment closed at 519.38 times subscription, with the HNI portion alone subscribed 856.35 times.

Unlike retail, allotment in this category is proportional. However, given the scale of oversubscription, the effective allocation per applicant is expected to be very small, and many applicants may receive no shares.

The QIB segment in the Modern Diagnostic IPO was subscribed 193.51 times, reflecting strong institutional participation. Allotment in this category is handled through institutional allocation mechanisms rather than a lottery.

While QIB allotment does not directly impact retail outcomes, the high subscription highlights broad-based market confidence, forming the backdrop against which the overall IPO allotment status will be finalised.

The Modern Diagnostic IPO has moved firmly into the allotment phase after closing with a blockbuster overall subscription of 350.49 times, reflecting intense investor demand across categories.

The issue was subscribed 519.38 times in the non-institutional investor segment, led by a massive 856.35 times subscription in the HNI portion, while the retail category closed at 342.46 times. Institutional participation was also strong, with the QIB segment subscribed 193.51 times.

With subscription levels running far ahead of the shares on offer, investor attention has now shifted to the IPO allotment status, which will determine final allocations, particularly in the retail category where allotment follows a lottery-based mechanism.

The allotment status update is now the next key trigger, ahead of refunds, share credit, and the stock’s listing on the BSE SME platform.

After closing with an extraordinary subscription response, the Modern Diagnostic IPO has firmly moved into the allotment phase. The issue saw overwhelming demand across retail, HNI, and institutional categories, making allotment highly competitive.

With the subscription far exceeding the shares on offer, investor attention has now shifted from headline subscription numbers to the IPO allotment status, which will determine final allocations, especially in the retail segment where allotment follows a lottery-based mechanism.

As the post-issue process progresses, the allotment status update is the next key trigger, followed by refunds, share credit, and listing on the BSE SME platform.

With the Modern Diagnostic IPO allotment status now the central focus for investors, the post-issue timeline has entered a crucial phase. The IPO, which was open from December 31, 2025 to January 2, 2026, drew exceptionally strong demand and is now moving toward allotment and listing.

The allotment status is expected to be finalised shortly, after which successful applicants will see shares credited to their demat accounts. The stock is scheduled to list on January 7, 2026 on the BSE SME platform.

As of today, investors are closely tracking updates on the IPO allotment status, which will set the tone for refunds, share credit, and the company’s market debut.

As investors await the Modern Diagnostic IPO allotment status, a look at the key issue details provides context ahead of allotment and listing.

The Modern Diagnostic and Research Centre IPO was open for subscription from December 31, 2025 to January 2, 2026, with shares priced in the range of ₹85–₹90 per share. The IPO had a total issue size of ₹37 crore, with a lot size of 1,600 shares, translating into an application value of ₹1.44 lakh at the upper end.

Following the close of bidding, the immediate focus remains on the IPO allotment status, which is expected to be finalised shortly. Once completed, shares are scheduled to list on January 7, 2026 on the BSE SME platform.

Investors are advised to keep their PAN or application details ready as the allotment status update is the next key milestone in the post-IPO timeline.

As investors closely track the Modern Diagnostic IPO allotment status, attention is also on how the company plans to deploy the funds raised through the public issue.

The IPO was a pure fresh issue, and the proceeds will be utilised across key business priorities:

• Capital expenditure for medical equipment at diagnostic centres and laboratories: ₹20.69 crore (55.92 percent)
• Working capital requirements: ₹11.6 crore (31.35 percent)
• Repayment of certain outstanding borrowings: ₹4.5 crore (12.16 percent)
• General corporate purposes: ₹0.21 crore (1 percent)

With the issue now closed and the IPO allotment status expected shortly, investors are watching the post-issue process closely ahead of refunds, share credit, and listing on the BSE SME platform.

As investors track the Modern Diagnostic IPO allotment status, attention is also on the structure of the issue, which is a pure fresh issue.

The IPO had a total issue size of ₹37 crore, with the entire amount raised through a fresh issue. There was no offer for sale, meaning all IPO proceeds will go directly to the company.

With the issue now closed and the IPO allotment status awaited, the next key milestones remain allotment finalisation, refund initiation, share credit, and listing on the BSE SME platform.

With the Modern Diagnostic IPO allotment status now the key focus for investors, the post-issue process has entered its crucial phase following the closure of bidding on January 2, 2026.

The allotment status for the Modern Diagnostic IPO is scheduled to be finalised on January 5, 2026. Once the allotment is completed, investors will be able to check their allotment status online using PAN, application number, or demat details on the official registrar and exchange platforms.

Following the allotment status update:

• Refunds or UPI unblocking for non-allottees are expected to begin on January 6, 2026
• Shares will be credited to demat accounts on January 6, 2026
• The stock is scheduled to list on the BSE SME platform on January 7, 2026

For now, investors are advised to closely monitor the allotment status update, which will be the first and most important milestone before refunds, share credit, and listing take place.

As investors track the Modern Diagnostic IPO allotment status, it is important to keep the required details ready before checking the allotment outcome online.

To check allotment status on the registrar or BSE website, investors may need any one of the following details:

• PAN used while applying for the IPO
• Application number generated at the time of bidding
• DP ID and Client ID (for demat-based applications)
• Bank account number with IFSC (as applicable on the registrar portal)

Among these, PAN is the most commonly used and reliable option, especially for UPI-based applications.

Investors are advised to use the same details that were entered during the IPO application to avoid errors while checking the allotment status.

As the Modern Diagnostic IPO allotment process moves closer to completion, investors should be aware of the next steps once the allotment is finalised.

For applicants who receive allotment, shares will be credited to the demat account ahead of listing. In the case of non-allottees, the blocked funds under ASBA or UPI will be unblocked automatically, with no action required from the investor.

Following completion of allotment and fund unblocking, market participants can track the stock on its scheduled listing on the BSE SME platform, which will mark the company’s debut on the exchange.

With the Modern Diagnostic IPO allotment status now in focus, the allotment process is currently underway following the closure of the issue. The allotment is expected to be finalised shortly after bid reconciliation and verification are completed.

Once finalised, investors will be able to check the Modern Diagnostic IPO allotment status online using their PAN, application number, or demat details on the official registrar and stock exchange platforms.

Market participants are advised to keep their application credentials ready as the allotment status update is expected soon.

As investors await the Modern Diagnostic IPO allotment outcome today, it is important to understand what happens in case shares are not allotted, especially given the exceptionally high oversubscription across retail and non-institutional categories.

For applicants who do not receive allotment, the amount blocked under ASBA or UPI will be released automatically to the linked bank account. Investors are not required to raise any refund request or take any action.

Retail allotment in such heavily oversubscribed issues follows a lottery-based mechanism, and applying for multiple lots does not increase the probability of allotment.

With competition for shares remaining intense, investors are advised to monitor their bank account and demat status as the allotment process progresses.

Investors who applied for the Modern Diagnostic IPO can check their allotment status on the BSE website once the allotment process is completed.

Steps to check allotment on BSE:​

1. Visit the BSE application status page:
   https://www.bseindia.com/investors/appli_check.aspx
2. Select Issue Type as Equity.
3. Enter Modern Diagnostic and Research Centre Limited in the Issue Name field.
4. Enter either:
   • Application Number, or
   • PAN number
5. Complete the captcha and click Search.

The allotment status will be displayed on the screen.

The Modern Diagnostic and Research Centre Limited IPO has wrapped up bidding with an extraordinary response, closing at an overall subscription of over 350 times, driven by heavy participation across retail, HNI, and institutional investors.

With demand running far ahead of the available shares, especially in the retail and HNI categories, investor attention has now shifted from subscription numbers to the allotment outcome. Given the scale of oversubscription, allotment in the retail segment is expected to follow a lottery-based process, making results highly competitive.

The allotment status is expected to be finalised shortly, after which investors will be able to check their allocation using PAN or application details on the official registrar and exchange platforms.

As the dust settles on one of the most heavily subscribed SME IPOs in recent times, the next key trigger for the market will be who gets the shares and who doesn’t.